stockrowSolventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
Follow SOLV
Alert me
Solventum Corporation 10-Q filed Aug 8, 2025
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 9, 2025: 29 added · 7 removed · 33 modified; 7 with only figures updated; 1 moved without change
-
Modified · Operating Segments and Sales Change Information
Solventum manages its operations in four business segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. On February 25, 2025, the Company entered into a
definitive agreementTransaction Agreement to sell its Purification and Filtration business to Thermo Fisher Scientific Inc. (“Buyer”) for $4.1 billion. On June 25, 2025, the Company and Buyer entered into an additional Agreement to exclude the Company’s Water Business from the scope of the Purification and Filtration business to be acquired by Buyer and reduce the cash consideration at closing of the transaction to approximately $4.0 billion. The closing of the transaction is expected to be completed by the end ofthe2025calendar year, subject to regulatory approvals and customary closing conditions. The company intends to use the net proceeds from the transaction primarily to pay down a portion of the Company’s outstanding debt through the pay down of our term loan and bond buybacks.